The identification of activated forms of the epidermal growth factor receptor (EGFR) as oncogenic drivers in non–small cell lung cancer (NSCLC) has rendered this receptor a key target in precision medicine [1]. Here, EGFR is linked to non-small cell lung carcinoma.